GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring tripeptide found in human blood, saliva, and urine that binds and delivers copper(II) ions to enzymes involved in tissue repair. First isolated from human plasma in the 1970s, it is studied for its roles in skin renewal, wound healing, and extracellular matrix remodeling. It is not FDA-approved for any indication and is currently classified as investigational, available mainly through compounding pharmacies and research settings.

What is GHK-Cu

GHK-Cu is a tripeptide made up of three amino acids: glycine, histidine, and lysine, combined with a copper(II) ion. It occurs naturally in the human body and is present in measurable concentrations in plasma, saliva, and urine. Researcher Loren Pickart first identified and characterized it from human plasma albumin fractionation in the 1970s, sparking several decades of preclinical research into its biological roles.

One of the more notable aspects of GHK-Cu is that its plasma levels decline with age. Studies have documented a drop from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. This age-related decline has motivated researchers to investigate whether restoring or augmenting GHK-Cu levels could support tissue maintenance in older adults, though this hypothesis remains under investigation rather than established clinical fact.

GHK-Cu is structurally distinct from synthetic growth peptides or receptor agonists. It works primarily by binding and transporting copper ions to copper-dependent enzymes, making it more of a biological signal or cofactor carrier than a direct growth-factor mimic.

How it works

GHK-Cu exerts its effects through several intersecting mechanisms, all centered on its ability to deliver copper to enzymes that regulate the extracellular matrix.

Copper-dependent enzyme activation. GHK-Cu is thought to activate lysyl oxidase, a copper-dependent enzyme responsible for cross-linking collagen and elastin fibers. This cross-linking is critical for the structural integrity and tensile strength of connective tissue, including skin and tendons.

MMP modulation. Research suggests GHK-Cu influences matrix metalloproteinases (MMPs), a family of enzymes that break down damaged matrix components. It appears to upregulate MMP-2, which helps clear degraded collagen, while simultaneously promoting new matrix synthesis. This coordinated remodeling activity distinguishes it from simple growth-promoting compounds.

Broad gene expression effects. Analysis of Broad Institute Connectivity Map data has indicated that GHK-Cu may influence expression of a large proportion of human genes at meaningful thresholds. Categories showing apparent upregulation include anti-inflammatory signaling, antioxidant defense genes (such as superoxide dismutase and catalase), and genes tied to skin barrier function. The clinical significance of these gene-expression findings remains to be established in controlled human trials.

NF-kB and inflammation. Some studies suggest GHK-Cu modulates NF-kB signaling, a central pathway in inflammatory responses, and may reduce pro-inflammatory cytokines such as TNF-alpha in preclinical wound models.

What the research says

The evidence base for GHK-Cu is predominantly preclinical (cell culture and animal studies) with a smaller body of early human clinical data, mostly in dermatology.

Skin and collagen. In vitro studies have shown GHK-Cu stimulates collagen type I and III synthesis in human fibroblasts at very low concentrations. A 12-week placebo-controlled clinical study in 67 women with photodamaged skin reported improvements in skin firmness, laxity, fine line depth, and clarity with twice-daily topical GHK-Cu application. Effect sizes were moderate and results are not yet replicated in large independent trials.

Wound healing. Animal models show accelerated wound closure and reduced inflammatory markers with GHK-Cu gel application. Published human clinical wound data is limited; most of the wound healing evidence comes from in vitro and rodent studies.

Hair follicle activity. Several preclinical studies have observed that copper-binding peptides related to GHK-Cu can enlarge hair follicles and stimulate follicle activity, including conversion of vellus follicles toward larger, terminal-like follicles. These results are not consistently replicated across studies, and human clinical evidence for reversing established hair loss is weak.

Antioxidant and barrier support. Genomic analyses suggest GHK-Cu may upregulate antioxidant and skin-barrier genes, which could have implications for aging skin, but this evidence is primarily in silico and in vitro at this stage.

Overall, GHK-Cu has an interesting and relatively well-documented preclinical research profile. The gap between preclinical findings and confirmed clinical outcomes in humans remains significant.

Typical dosing

GHK-Cu is not FDA-approved, and no established clinical dosing standard exists. What follows represents ranges commonly reported in research literature and practitioner protocols, not a treatment recommendation.

Topical formulations are the most studied and are available through compounding pharmacies with appropriate provider involvement. Injectable protocols are largely self-directed and lack controlled clinical safety or efficacy data. Cycle lengths vary; some protocols describe periods of 4-8 weeks followed by a break, though this is convention rather than evidence-based guidance.

Caution: Dosing information found online or in community forums is not a substitute for medical supervision. If you are considering GHK-Cu, work with a licensed healthcare provider who can assess your individual situation.

For help calculating vial concentration and dose volumes, the free reconstitution calculator at /calculators can assist. If you are using injectables, reviewing how to reconstitute peptides and injection site rotation best practices is recommended before starting.

Side effects and safety

GHK-Cu is generally considered to have a favorable tolerability profile based on available research, though comprehensive long-term human safety data is limited.

Commonly reported effects:

• Local skin irritation, mild redness, or transient itching with topical application
• Injection site reactions (redness, minor swelling) with subcutaneous use
• Skin discoloration has been reported in some cases with topical use, particularly with prolonged application

Less-defined risks:

• Copper accumulation is a theoretical concern with high-dose or long-term injectable use, though GHK-Cu binds copper in a regulated complex rather than delivering free ionic copper
• Interactions with other compounds or medications have not been systematically studied
• Long-term systemic safety data from controlled human trials is not available

Who should exercise particular caution: People with copper metabolism disorders (such as Wilson's disease), those who are pregnant or breastfeeding, and individuals taking medications that interact with copper or metalloproteinase activity should discuss use with a physician before starting.

GHK-Cu is not known to be acutely toxic at doses used in research, and its preclinical safety record is relatively clean. However, the absence of evidence for serious harm is not the same as evidence of safety across all populations and dosing contexts.

Tracking GHK-Cu with Redose

If you are running a GHK-Cu protocol, Redose makes it straightforward to stay on schedule. Log each dose in one tap, track your vial inventory with automatic countdowns, and use the built-in reconstitution calculator to confirm concentration before every use. The app works offline and syncs automatically, so your dose history is always with you. Download Redose at /#download for iPhone and Android.

This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.